Study examines desmopressin’s hemostatic effect in anesthetized dogs

Version 2

Desmopressin may have a clearer perioperative role in dogs than previously documented. In a 2026 Open Veterinary Journal study, Suzuki, Tanaka, Kanno, and colleagues found that DDAVP dose-dependently shortened buccal mucosal bleeding time and increased factor VIII antigen within 60 minutes in healthy anesthetized dogs, offering new controlled data in a setting that matters directly to surgery and procedural planning. (openveterinaryjournal.com)

That matters because DDAVP is not new to veterinary medicine, but the evidence base has been patchy and often tied to specific disease states. Earlier work showed shortened buccal mucosal bleeding times after DDAVP in Doberman Pinschers with von Willebrand disease, and case reporting has described use in dogs with aspirin-associated coagulopathy. In practice, clinicians have also used desmopressin before procedures in selected bleeding-risk patients, though its benefit is not guaranteed and cost can be a limiting factor. (pubmed.ncbi.nlm.nih.gov)

The new paper focused on healthy Beagle dogs under general anesthesia, not naturally occurring bleeding disorders. According to the journal abstract and article page, the investigators evaluated changes in buccal mucosal bleeding time, a standard in-clinic screening test for primary hemostasis, alongside plasma factor VIII antigen. Their conclusion was that DDAVP produced a dose-dependent shortening of BMBT and a rise in FVIII:Ag at 60 minutes, and that the findings should be treated as preliminary support for further investigation in surgical patients. (openveterinaryjournal.com)

That framing is important. BMBT is still commonly used in dogs to assess primary hemostasis, but it is a screening tool with practical limitations. Cornell’s comparative coagulation guidance notes that the test is performed after anesthetic administration and requires careful technique, while Merck states that canine BMBT is generally interpreted as normal when it is under 4 minutes. Other veterinary clinical pathology references note that sedation or anesthesia can mildly prolong BMBT and that repeatability can vary within the same patient. (vet.cornell.edu)

There does appear to be some alignment between the study and broader clinical thinking. In a recent dvm360 interview on bleeding management in small animal patients, criticalist Sean Bini said some clinicians give desmopressin 20 to 30 minutes before surgery to stimulate release of von Willebrand factor, especially in the context of von Willebrand disease, while also cautioning that response is inconsistent and injectable desmopressin can be expensive. Older dvm360 proceedings similarly describe DDAVP as a preventive option for milder cases or minor surgery in dogs with von Willebrand disease. (dvm360.com)

Why it matters: For veterinary teams, this study helps narrow an evidence gap around DDAVP use during anesthesia, when many bleeding-risk decisions actually get made. It does not show that desmopressin should be used routinely in healthy dogs, and it does not replace disease-specific diagnostics such as platelet count, von Willebrand factor testing, or broader coagulation workups. What it does suggest is that DDAVP can produce measurable short-term hemostatic effects in anesthetized dogs, which may strengthen its rationale as an adjunct in selected procedural cases, especially where primary hemostatic defects are a concern. (openveterinaryjournal.com)

The study also raises practical questions for referral, emergency, and surgical services: which patients are most likely to benefit, what dose and timing are optimal, and whether changes in BMBT or FVIII:Ag translate into less clinically meaningful bleeding. Because the current work was done in healthy dogs, the real test will be performance in patients with von Willebrand disease, drug-associated platelet dysfunction, liver disease, or other acquired coagulopathies, where prior smaller studies and case reports have hinted at benefit. (openveterinaryjournal.com)

What to watch: Look for prospective studies in clinical surgical populations, especially those comparing DDAVP timing, dose, and patient selection against real bleeding outcomes rather than screening-test changes alone. (openveterinaryjournal.com)